In the recent application round, the NWO approved the TakeOff2 application submitted by NC Biomatrix. The company will receive the 250.000€ TakeOff2 loan to perform the „First in Man“ pilot clinical trial to clinically validate the company`s first product – VitaDisc – a new injectable therapy to treat spinal disc degeneration and associated back pain.
CEO Bob Guilleaume stated, „ We are very grateful for the approval of our
TakeOff2 application. This funding plus the equity round the company is in the process of closing will provide NC Biomatrix with the funding necessary to achieve a key milestone of initial clinical validation and creates the foundation for a larger financing round in 2022 for the multicenter international clinical trial and regulatory submissions for key markets. Our team is highly dedicated to bringing this new innovative technology to the market.“